Latest News

ACTINIUM PHARMACEUTICALS: Actinium Highlights Actimab-A and Venetoclax Synergies Observed in New Studies Presented at AACR

Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) highlighted data from its poster presentation at the AACR or American Association of Cancer Research annual Meeting 2019 demonstrating that the targeted radiation delivered by Actimab-A to CD33 expressing cells can deplete MCL-1 levels in tumor cells, thereby removing a mechanism of resistance and rendering them more susceptible to venetoclax.

Emma's Torch refugee culinary training group among 'Renewal Awards' finalists

A Brooklyn-based group that works to empower refugees through culinary training is one of 15 nonprofits in the U.S. selected to be finalists in The Atlantic and Allstate's "The Renewal Awards," according to a recent press release.

BREAST CANCER RESEARCH FOUNDATION: BCRF Announces Launch of New Precision Prevention Initiative

BCRF is dedicated to creating a future where women can benefit from the wide range of innovative strategies to reduce their breast cancer risk, but also to personalize risk assessment, screening and intervention.

KOHL'S: Kohl’s is Delivering Joy This Holiday Season

The holiday season is here and the Operation Give Joy series provides a closer look at how Kohl’s operations efforts are delivering an easy, convenient shopping experience to customers.

KOHL'S: Holiday Decorating with LC Lauren Conrad

One of Lauren Conrad’s favorite things to do during the holidays is decorating her home.

BREAST CANCER RESEARCH FOUNDATION: Immunotherapy Extends Lives for Patients with Advanced Triple Negative Breast Cancer

Triple negative breast cancer is an aggressive disease with a high likelihood of spreading to other tissues, a process called metastasis.

CAPITAL REGION CHAMBER: Capital Region Chamber’s Angela Dixon Chosen to Inaugural Class of Education and Workforce Fellowship Program

In response to the needs of state and local chambers, the U.S. Chamber of Commerce Foundation recently launched the new premier business leadership program to help address the most pressing education and workforce issues.

BARNES & NOBLE: Barnes & Noble Announces Strategic Alternatives Process

Barnes & Noble, Inc. (NYSE: BKS) today announced that its Board of Directors has decided to enter into a formal review process to evaluate strategic alternatives for the Company.

ALTICE USA: Altice Advantage Internet Low-Cost Broadband Service Extended to Households with New York City Public School Children

Altice USA (NYSE: ATUS) today hosted an event with Bronx Borough President Ruben Diaz Jr. at the Kips Bay Boys & Girls Club to announce the expansion of its low-cost broadband service, now called Altice Advantage Internet, to all qualifying households with a child attending New York City public schools in the Optimum service area.

AMERICAN GERIATRICS SOCIETY: New Report on Assessing Mobility Has Experts Moving Toward Consensus on Care We Need as We Age

Experts at the American Geriatrics Society (AGS) today unveiled a list of recommendations to help health systems prioritize a vital function for us all as we age: mobility.

DIGIDAY: Facebook rolls out system to include news publishers in its controversial Ad Archive

Facebook is moving forward with its controversial Ad Archive with a new system being announced today that will decide where to include individual publishers in the archive.

RENSSELAER COUNTY REGIONAL CHAMBER OF COMMERCE: Marketing Agency Expands Operations with New Office in Saratoga Springs

Adworkshop, an integrated marketing agency headquartered in Lake Placid, NY, announced its expansion into Saratoga Springs, NY with a new office near downtown to accommodate its growing client roster.

BRISTOL-MYERS SQUIBB: Bristol-Myers Squibb-Pfizer Alliance ACROPOLIS™ Real-World Data Program Grows to Sample Size of Nearly One Million Lives Worldwide

The Bristol-Myers Squibb-Pfizer Alliance will present 15 Eliquis® (apixaban) posters at the ESC Congress 2018 held in Munich, Germany, August 25-29, 2018.

BRISTOL-MYERS SQUIBB: U.S. Food and Drug Administration Approves Opdivo® (nivolumab) as the First New Medication in Nearly 20 Years for Certain Patients with Previously Treated Small Cell Lung Cancer

Bristol-Myers Squibb Company (NYSE:BMY) today announced that Opdivo (nivolumab) received approval from the U.S. Food and Drug Administration (FDA) as the first and only Immuno-Oncology treatment option for patients with metastatic small cell lung cancer (SCLC) whose cancer has progressed after platinum-based chemotherapy and at least one other line of therapy.

Metro Business Network